Please assess the completion status of the following clinical trial:

Trial Title: Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol~* A male or female between, and including, 11 and 17 years of age at the time of the first dose of vaccine.~* Written informed consent obtained from the subject/ from the parent or guardian of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Previously completed routine childhood vaccinations to the best of his/her/the parents'/guardians' knowledge.~* If the subject is female and of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for two months after completion of the vaccination series.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.~* Planned administration/ administration of a vaccine not foreseen by the study protocol within one month of the dose of vaccine.~* Previous vaccination with meningococcal polysaccharide vaccine of serogroup A, C, W-135 and/or Y within the last five years.~* Previous vaccination with meningococcal polysaccharide conjugate vaccine of serogroup A, C, W-135 and/or Y.~* Previous vaccination with tetanus toxoid within the last month.~* Previous vaccination with hepatitis A and/or hepatitis B vaccine.~* Seropositivity for hepatitis A IgG, hepatitis B surface antigen, hepatitis B core antibody and/or hepatitis B surface antigen at screening.~* History of hepatitis A, hepatitis B and/or Neisseria meningitidis infection.~* Known exposure to hepatitis A and/or hepatitis B virus within three months preceding the first dose of study vaccine.~* Any confirmed or suspected immunosuppressive or immunodeficient condition (congenital or secondary), including human immunodeficiency virus (HIV) infection, based on medical history and physical examination.~* A family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.~* History of reactions or allergic disease likely to be exacerbated by any component of either vaccine.~* Major congenital defects or serious chronic illness.~* Acute disease at the time of enrolment.~* Administration of immunoglobulins and/or any blood products within the three months preceding the dose of study vaccine or planned administration during the study period.~* Pregnant or lactating female.~* History of chronic alcohol consumption and/or drug abuse.~* Female planning to become pregnant or planning to discontinue contraceptive precautions.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Nimenrix + Twinrix Group (Type: EXPERIMENTAL): Subjects received 1 dose of Nimenrix™ vaccine at Month 0 and 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.
- Nimenrix Group (Type: ACTIVE_COMPARATOR): Subjects received 1 dose of Nimenrix™ vaccine at Month 0.
- Twinrix Group (Type: ACTIVE_COMPARATOR): Subjects received 1 dose of Twinrix™ vaccine at Months 0, 1 and 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete